These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6418548)

  • 41. Identification of the urinary metabolites of tacrine in the rat.
    Hsu RS; Shutske GM; Dileo EM; Chesson SM; Linville AR; Allen RC
    Drug Metab Dispos; 1990; 18(5):779-83. PubMed ID: 1981736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
    Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
    Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of metabolites from benzo[a]pyrene oxidation by ligninolytic enzymes of Polyporus sp. S133.
    Hadibarata T; Kristanti RA
    J Environ Manage; 2012 Nov; 111():115-9. PubMed ID: 22835655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On the metabolism of ditazole in man.
    Maurer H; Kleff I
    Arzneimittelforschung; 1988 Dec; 38(12):1843-5. PubMed ID: 2907728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs.
    Hoffmann KJ
    Drug Metab Dispos; 1986; 14(3):341-8. PubMed ID: 2872036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The metabolism of 8-methoxypsoralen in man.
    Schmid J; Prox A; Reuter A; Zipp H; Koss FW
    Eur J Drug Metab Pharmacokinet; 1980; 5(2):81-92. PubMed ID: 7398681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolism of the anticonvulsant agent zonisamide in the rat.
    Stiff DD; Zemaitis MA
    Drug Metab Dispos; 1990; 18(6):888-94. PubMed ID: 1981533
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of the metabolites of a new hypoglycaemic agent, midaglizole, in dogs.
    Nakaoka M; Hakusui H
    Xenobiotica; 1987 Nov; 17(11):1329-39. PubMed ID: 3433802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biotransformation of a 1,5-benzodiazepine, triflubazam, by man.
    Alton KB; Grimes RM; Shaw C; Patrick JE; McGuire JL
    Drug Metab Dispos; 1975; 3(5):352-60. PubMed ID: 241616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
    Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
    Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolism of flumecinol in humans.
    Klebovich I; Vereczkey L; Tóth E; Tamás J; Mák M; Jalsovszky G; Holly S
    Xenobiotica; 1987 Oct; 17(10):1247-58. PubMed ID: 3424871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of urinary metabolites of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in rat, rabbit and dog.
    Komuro M; Ishida R; Uchida H
    Arzneimittelforschung; 1992 Jan; 42(1):48-55. PubMed ID: 1586380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overview of the pharmacokinetics of fluvoxamine.
    van Harten J
    Clin Pharmacokinet; 1995; 29 Suppl 1():1-9. PubMed ID: 8846617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study.
    Burhanuddin K; Badhan R
    Metabolites; 2022 Dec; 12(12):. PubMed ID: 36557319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.
    Alqahtani S; Kaddoumi A
    Clin Pharmacokinet; 2016 Aug; 55(8):957-69. PubMed ID: 26914771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.
    Mast N; Linger M; Clark M; Wiseman J; Stout CD; Pikuleva IA
    Mol Pharmacol; 2012 Nov; 82(5):824-34. PubMed ID: 22859721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluvoxamine in the treatment of anxiety disorders.
    Irons J
    Neuropsychiatr Dis Treat; 2005 Dec; 1(4):289-99. PubMed ID: 18568110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.
    Crone CC; Gabriel GM
    Clin Pharmacokinet; 2004; 43(6):361-94. PubMed ID: 15086275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluvoxamine as an adjunctive agent in schizophrenia.
    Silver H
    CNS Drug Rev; 2001; 7(3):283-304. PubMed ID: 11607044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.